Sorafenib-d4

• Description:

  Sorafenib-d4 (Bay 43-9006-d4) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

• Product Name Alternative:

  Bay 43-9006-d4

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C (C1=NC=CC (OC2=C ([2H]) C ([2H]) =C (NC (NC3=CC=C (Cl) C (C (F) (F) F) =C3) =O) C ([2H]) =C2[2H]) =C1) NC

• Molecular Formula:

  C21H12D4ClF3N4O3

• Molecular Weight:

  468.85

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64 (19) :7099-109.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  1207560-07-3